Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H ( (HK:9989) ) just unveiled an announcement.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. reported its consolidated annual results for the year ending December 31, 2024, showing a slight decrease in revenue to RMB5,258.9 million compared to the previous year. However, the company achieved a significant increase in gross profit to RMB1,739.3 million, with a gross profit margin of 33.1%. The company also reported a profit attributable to equity holders of RMB646.7 million, a notable recovery from the previous year’s loss. The Board has proposed a final cash dividend, reflecting a positive outlook for stakeholders.
More about Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is a pharmaceutical company based in China, primarily engaged in the production and sale of finished dose pharmaceutical products, active pharmaceutical ingredients (API), and contract development and manufacturing organization (CDMO) services.
YTD Price Performance: 17.17%
Average Trading Volume: 3,044,091
Technical Sentiment Signal: Sell
Current Market Cap: HK$16.52B
For detailed information about 9989 stock, go to TipRanks’ Stock Analysis page.